Stay updated on Atezolizumab vs Durvalumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab vs Durvalumab in NSCLC Clinical Trial page.

Latest updates to the Atezolizumab vs Durvalumab in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the detailed study purpose and inclusion/exclusion criteria for a clinical trial on non-small cell lung cancer (NSCLC). Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference14%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 7, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3.SummaryDifference0.1%
- Check59 days agoChange DetectedThe web page has been updated to reflect a decrease in the number of study locations from 199 to 178, with significant additions of new locations in various countries, including the United States, Brazil, China, and several European nations.SummaryDifference28%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
Stay in the know with updates to Atezolizumab vs Durvalumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab vs Durvalumab in NSCLC Clinical Trial page.